UltraGreen ai (ULG) investor relations material

Executive summary

• Achieved strong Q1 FY2026 with 281,000 vials shipped, representing 7.8% quarter-over-quarter and 8.7% year-over-year growth; underlying double-digit growth when excluding prior year backorders.

• Broad-based improvement in volumes across all geographies, with supply normalization and expanded lyophilization capacity.

• Global adoption trends remain positive, with expansion into 41 approved countries and over 20 additional markets in the approval pipeline.

• Key product adoption driven by clinical evidence, new indications, and expansion into high-volume procedures and new geographies.

Financial highlights

• Q1 volume growth of 8% sequentially; normalized double-digit growth year-over-year after adjusting for 2025 backorder effects.

• 281,000 vials shipped in Q1 FY2026, reflecting robust demand and operational recovery.

• Lyophilization capacity increased from 1 to 4 lines, with a 5th line in qualification, supporting up to 3.5 million vials annually.

• Revenue guidance for 2026 remains $170–$190 million, with current trends supporting this outlook.

• U.S. market down 20% in Q1 due to prior year backlog fulfillment; strong growth in Italy (+26%), UK (+13%), DACH/Spain (>30%), and APAC (almost doubling).

Outlook and guidance

• Management confident in achieving full-year 2026 guidance, expecting continued double-digit volume growth in H1 2026.

• No significant seasonality observed; Q2 expected to be strong with no exceptional items anticipated.

• Full-year impact expected from US price increase and further market expansion.

• Progressing regulatory pathways for quantification software in EU and US, with new product launches anticipated.

• New market approvals factored into guidance, with growth expected to ramp as adoption increases over 6–9 months.